Management ChangeJul 8, 2026, 04:06 PM
Calidi Biotherapeutics Appoints Sandra Gurrola as VP Finance
AI Summary
Calidi Biotherapeutics announced the appointment of Sandra Gurrola as VP Finance, Controller. In connection with her new role, the company's Compensation Committee and Board of Directors approved an inducement non-qualified stock option grant for 100,000 shares. The options have an exercise price of $0.15 and will vest over four years, with the first 25% vesting on July 6, 2027.
Key Highlights
- Sandra Gurrola appointed as VP Finance, Controller.
- Granted inducement non-qualified stock option for 100,000 shares.
- Exercise price set at $0.15, based on July 6, 2026 closing price.
- Stock options vest over four years, with 25% vesting on July 6, 2027.
- Remaining options vest in equal monthly installments until July 6, 2030.
- Grant is an inducement for employment under NYSE American LLC Company Guide Section 711.
Price Impact
More from CLDI